DRMA's Business Model
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.dermatarx.com |
| CEO (Chief Executive Officer) | Gerald T. Proehl |
| Number of Employees | |
| IPO date | August 13, 2021 |
DRMA Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 3525 Del Mar Heights Road |
| City | San Diego |
| State | CA |
| Phone | 858 800 2543 |
| Zip Code | 92130 |
| Other Identifiers | |
| CIK | 0001853816 |
| ISIN | US2498454055 |
| CUSIP | 249845108 |
| Open | 0.66 |
| Previous Close | 0.695 |
| Volume | 693.9 Thou. |
| Average Volume | 158.1 Thou. |
| Day’s Range | 0.6201 – 0.6777 |
| 52 Week Range | 0.574-5 |
| MA (50) | 0.7369 |
| MA (200) | 1.11186 |
| Market Cap | 4.02 Mil. |
| Shares Out. | 6.38 Mil. |
| Earnings Date | Aug 07, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
